2679 related articles for article (PubMed ID: 7923243)
1. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine.
Berd D; Maguire HC; Mastrangelo MJ; Murphy G
Cancer Immunol Immunother; 1994 Sep; 39(3):141-7. PubMed ID: 7923243
[TBL] [Abstract][Full Text] [Related]
2. Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine.
Sato T
Cancer Immunol Immunother; 1996 Nov; 43(3):174-9. PubMed ID: 9001571
[TBL] [Abstract][Full Text] [Related]
3. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine.
Sato T; Maguire HC; Mastrangelo MJ; Berd D
Clin Immunol Immunopathol; 1995 Jan; 74(1):35-43. PubMed ID: 7994925
[TBL] [Abstract][Full Text] [Related]
4. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.
Sato T; Bullock TN; Eisenlohr LC; Mastrangelo MJ; Berd D
Clin Immunol Immunopathol; 1997 Dec; 85(3):265-72. PubMed ID: 9400626
[TBL] [Abstract][Full Text] [Related]
5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
6. Autologous, hapten-modified vaccine as a treatment for human cancers.
Berd D; Kairys J; Dunton C; Mastrangelo MJ; Sato T; Maguire HC
Semin Oncol; 1998 Dec; 25(6):646-53. PubMed ID: 9865679
[TBL] [Abstract][Full Text] [Related]
7. Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy.
Murphy GF; Radu A; Kaminer M; Berd D
J Invest Dermatol; 1993 Mar; 100(3):335S-341S. PubMed ID: 8440919
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
9. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma.
Kowalczyk D; Skorupski W; Kwias Z; Nowak J
Br J Urol; 1997 Oct; 80(4):543-7. PubMed ID: 9352689
[TBL] [Abstract][Full Text] [Related]
11. Memory T-lymphocytes are the main population of tumor-infiltrating lymphocytes obtained from human primary liver tumors.
Shimizu Y; Watanabe A; Whiteside TL
J Hepatol; 1992 Sep; 16(1-2):197-202. PubMed ID: 1484153
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Smith CV; Pecorelli S; Radominska-Pandya A; Cannon MJ; Parham GP
Gynecol Obstet Invest; 2001; 51(4):254-61. PubMed ID: 11408737
[TBL] [Abstract][Full Text] [Related]
13. Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors.
Shimizu Y; Iwatsuki S; Herberman RB; Whiteside TL
Int J Cancer; 1990 Nov; 46(5):878-83. PubMed ID: 2146230
[TBL] [Abstract][Full Text] [Related]
14. M-Vax: an autologous, hapten-modified vaccine for human cancer.
Berd D
Expert Rev Vaccines; 2004 Oct; 3(5):521-7. PubMed ID: 15485331
[TBL] [Abstract][Full Text] [Related]
15. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor.
Yoshino I; Yano T; Murata M; Ishida T; Sugimachi K; Kimura G; Nomoto K
Cancer Res; 1992 Feb; 52(4):775-81. PubMed ID: 1737336
[TBL] [Abstract][Full Text] [Related]
16. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
17. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine.
Manne J; Mastrangelo MJ; Sato T; Berd D
J Immunol; 2002 Sep; 169(6):3407-12. PubMed ID: 12218163
[TBL] [Abstract][Full Text] [Related]
18. Autologous, hapten-modified vaccine as a treatment for human cancers.
Berd D
Vaccine; 2001 Mar; 19(17-19):2565-70. PubMed ID: 11257393
[TBL] [Abstract][Full Text] [Related]
19. Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.
Wu RC; Liu S; Chacon JA; Wu S; Li Y; Sukhumalchandra P; Murray JL; Molldrem JJ; Hwu P; Pircher H; Lizée G; Radvanyi LG
Clin Cancer Res; 2012 May; 18(9):2465-77. PubMed ID: 22307139
[TBL] [Abstract][Full Text] [Related]
20. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
